# 1. Financial Performance ## A. Key Figures * **Revenue (FY26):** **₹2,384 Cr** Consolidated (+65%) · **₹1,676 Cr** Anupam Standalone * **EBITDA (FY26):** **₹543 Cr** Consolidated (23% Margin) · **₹834 Cr** Pro-forma Combined * **PAT (FY26):** **₹222 Cr** Consolidated (9% Margin) · **₹160 Cr** FY25 Base * **Q4 FY26 Performance:** **₹639 Cr** Revenue (+26%) · **₹141 Cr** EBITDA (22% Margin) · **₹56 Cr** PAT (9% Margin) * **Operating Cash Flow (FY26):** **₹330 Cr** Consolidated · **₹274 Cr** Standalone * **Debt Position:** **₹1,500 Cr** Gross · **₹1,100 Cr** Net ## B. Revenue Growth * **Record Top-Line Achievement:** Delivered highest-ever annual revenue fueled by high-value chemistries and the successful commercial scale-up of molecules. * **Pro-forma Scale:** The combined entity (including Tanfac, Jayhawk, and Bliss) demonstrates a significantly larger footprint with total revenue exceeding **₹4,000 Cr**. ## C. Margins & Profitability * **Consistent Profitability:** Maintained stable margins despite shifts in product mix across Agro, Pharma, and Polymers, supported by strong execution. * **Bottom-Line Expansion:** Reported robust double-digit growth in PAT compared to the previous fiscal year. * **Tax Optimization:** Management expects a structural tailwind from a lower standalone tax rate of approximately **25%** moving forward. ## D. Cash Flow & Balance Sheet * **High Cash Conversion:** Operating cash flow significantly exceeded consolidated PAT, reflecting disciplined working capital and inventory management. * **Leverage Outlook:** Net debt is projected to rise to **₹1,400 Cr – ₹1,500 Cr** post-acquisition; management views this as sustainable against an estimated EBITDA range of **₹650 Cr – ₹800 Cr**. * **Debt Structure:** The balance sheet remains dominated by short-term obligations, with over two-thirds of gross debt tied to working capital loans. --- # 2. M&A & Strategic Initiatives ## A. Key Figures * **Bliss GVS Equity Stake:** **43.3% to 48.2%** Initial acquisition range · **26%** Additional open offer * **Bliss GVS Funding:** **₹300 Cr** Non-convertible debentures (NCDs) * **Bliss GVS Revenue Potential:** **~₹3,000 Cr** Peak capacity of current gross block * **Jayhawk Pro Forma Revenue:** **$76M** Annualized * **Pharma Revenue Mix:** **20%** Current (up from ~0%) ## B. Bliss GVS Acquisition * **Vertical Integration Strategy:** Acquisition transforms the company into an integrated life science platform, bridging the gap from **Key Starting Materials (KSM)** to **Finished Dosage Formulations (FDF)**. * **Regulatory & CDMO Catalyst:** Accesses a platform with **C. S. FDA, EU GMP, and WHO GMP** accreditations, positioned as the primary vehicle for future pharma CDMO/CMO opportunities. * **Financial Accretion:** Transaction expected to be **EPS accretive from day 1**, with full operational synergies and CDMO project expansions materializing within **6 to 18 months**. * **Accelerated Value Creation:** Management intends to scale the entity faster than the **four-year timeline** achieved with Tanfac, leveraging existing infrastructure and regulatory approvals. ## C. Jayhawk & Tanfac Integration * **Manufacturing Footprint:** Completion of the Jayhawk acquisition establishes a strategic **D. S. manufacturing base**, targeting high-growth sectors including **defense, semiconductors, and EVs**. * **Supply Chain Security:** Tanfac integration has secured the fluorination platform, providing uninterrupted access to **hydrofluoric acid** and assisting in securing new long-term contracts. * **Financial Timing:** Current results reflect only **32 days** of Jayhawk operations; full-year financial contributions are slated for **FY27**. ## D. Platform Synergies * **Cross-Pollination:** Strategy focuses on "unlocking synergies" by introducing Jayhawk’s services to the existing client portfolio and leveraging common customers across CDMO and specialty chemical segments. * **Operational Independence:** Acquired entities will remain **independent listed units** without plans for mergers; Anupam Rasayan will provide oversight and guidance while avoiding duplication of effort. * **Value Chain Segregation:** Management emphasizes that synergy is achieved through **segregated manufacturing steps** across organizations rather than corporate consolidation. ## E. Ownership & Leadership * **Leadership Continuity:** Following the "Tanfac model," the company will retain **professional management teams** at acquired entities to ensure operational stability. * **Succession-Driven Exit:** The Bliss acquisition was facilitated by the promoter's **succession planning** and a **two-year relationship** built on ethical alignment, rather than a competitive bidding war. * **Governance Transition:** Post-acquisition, erstwhile promoters will transition to **non-participating shareholders**, relinquishing control to Anupam Rasayan’s leadership. --- # 3. Product & Segment Performance ## A. Key Figures * **Revenue Mix (FY26):** **55%** Agrochemicals · **20%** Pharma · **18%** Performance Materials · **7%** Personal Care * **Pharma Revenue:** **₹339 Cr** FY26 (vs. ₹21 Cr FY22) * **High-Performance Materials Revenue:** **₹305 Cr** FY26 (vs. ₹97 Cr FY22) ## B. Vertical Mix & Strategic Evolution * **Diversified Global Platform:** The company has successfully transitioned into a multi-sector provider serving high-growth areas including **semiconductors, EV-related applications**, and performance materials. * **De-risking Strategy:** Strategic diversification has significantly reduced historical reliance on Agrochemicals, creating a more resilient and balanced portfolio. * **Growth Drivers:** Future momentum is expected to be anchored by the standalone business across Pharma and Polymers, bolstered by inorganic contributions from **Tanfac, Jayhawk, and Bliss**. ## C. Pharma & Polymers * **Exponential Pharma Scaling:** The segment has achieved massive multi-year growth and is projected to maintain sufficient organic momentum within the Indian market. * **Polymer Outlook:** Growth in the Polymer vertical is slated to be underpinned by the execution of **new projects**. ## D. High-Performance Materials * **Rapid Vertical Expansion:** Revenue from high-performance materials has seen a threefold increase over a four-year period, reflecting successful market penetration. --- # 4. Manufacturing & Capacity ## A. Key Figures * **Capacity Utilization:** **30%** current (Bliss GVS) · **60%–70%** medium-term target * **Asset Potential:** **₹2,500–2,600 Cr** standalone gross block · **₹3,500 Cr** peak revenue potential * **Maintenance Capex:** **₹50–75 Cr** annually (next 2–3 years) * **Acquisition Funding:** **₹300 Cr** via NCDs · **Balance** via non-dilutive quasi-equity ## B. Asset Utilization & Strategy * **Operational Scaling:** Management aims to more than double utilization rates at the acquired entity to drive top-line growth from its current base. * **Revenue Runway:** Existing standalone infrastructure possesses significant headroom to expand turnover without requiring major new capacity. * **Production Synergy:** Manufacturing will be optimized across separate plants (**Anupam, Bliss, Tanfac, Jayhawk**) to streamline delivery without necessitating legal consolidation. ## C. Capital Allocation * **Shift to Efficiency:** Following the completion of the primary capex cycle, the focus shifts from expansion to maintenance and operational efficiency. * **Strategic Financing:** The Bliss acquisition is structured to protect equity, utilizing a mix of debt and non-participative quasi-equity to avoid dilution. ## D. Halol Facility Expansion * **Dedicated CDMO Growth:** A targeted investment at the Halol site is earmarked for a major MNC pharmaceutical partner, distinct from existing facility objectives. * **High-Yield Returns:** The Halol investment is projected to be highly capital-efficient, with an expected asset turnover ratio of **4x to 5x**. --- # 5. Order Book & Customer Metrics ## A. Key Figures * **Order Book:** **₹14,000 Cr** Total Value * **Incremental Revenue:** **₹1,700 Cr** to **₹1,800 Cr** Annualized (6-year average) * **Product Launches:** **3** New specialty chemical products ## B. Pipeline Visibility * **Growth Drivers:** Future momentum anchored by the Elementium contract and EV sector entry, with Pharma and Polymers projected to outperform Agrochemicals. * **Revenue Conversion:** Robust order book provides high visibility, expected to yield significant annual top-line contributions over a multi-year horizon. ## C. Multinational Client Base * **Portfolio Expansion:** Market presence strengthened through the addition of multiple MNC clients and high-value specialty chemical offerings. * **CDMO Synergy:** Strategic acquisition enhances the value proposition and execution probability of a major **CDMO project** currently in development with a global MNC. ## D. Geography Mix * **Market Arbitrage:** Plans to leverage established U.S., European, and Indian footprints to drive volume for Bliss GVS’s underutilized **capex assets**. * **Geographic Complementarity:** Acquisition provides immediate entry into **African markets**, a region where the company previously had zero exposure. --- # 6. Risks & Specialty Chemicals ## A. Key Figures * **Working Capital (Pro Forma):** **215–220 days** Consolidated * **Working Capital (Ex-Jayhawk):** **240–250 days** Absolute ## B. Working Capital Cycle * **Efficiency Trajectory:** Management observes an encouraging downward trend in the cash conversion cycle and expects continued optimization as the business scales. * **Mix-Driven Improvement:** Anticipated growth in the **pharma and polymer segments** is identified as the primary catalyst for accelerating working capital reduction. ## C. Concentration Risks * **Market Expansion Strategy:** Management dismissed concerns regarding potential conflicts of interest in regulated markets, citing a total addressable market large enough to accommodate integrated players across the **KSM, API, and CDMO** value chains. --- # 7. Guidance & Outlook ## A. Key Figures * Revenue Growth Target: 2x increase over 3–5 years · 20% to 25% long-term CAGR * **EBITDA Margin Guidance:** **~24%** for FY26 (with upward bias) * **Capacity Utilization Target:** **60%–70%** range * **Revenue Milestone:** **$0.5 billion** long-term objective ## B. Revenue & Growth Strategy * **Sector-Specific Drivers:** Strategic focus on the commercialization of molecules within the **Pharma and Polymer** segments to underpin the doubling of top-line results. * **Market Positioning:** Management is adopting a more selective approach to product profiles, asserting that scaling to a **$500M** revenue base remains non-disruptive within the broader industry landscape. * **Growth Normalization:** Following a period of rapid recovery growth, the business is transitioning toward a sustainable long-term compounding trajectory. ## C. Operational & Margin Outlook * **Profitability Tailwinds:** While maintaining baseline guidance, management anticipates margin expansion as high-value pharma and polymer products ramp up. * **Operating Leverage:** Revenue growth is expected to scale linearly with asset utilization as the company moves toward its optimal capacity targets. * **Value Chain Integration:** Long-term strategy emphasizes offering a broader value chain to MNCs to enhance supply chain security and capture cross-business synergies.